Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Limited has released a notification regarding its ongoing on-market share buy-back program, stating that a total of 300,000 ordinary shares were repurchased on the previous day. This initiative highlights the company’s effort to optimize its capital structure, potentially improving shareholder value and reaffirming confidence in its financial position.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, specializing in diagnostic services and pathology testing, delivering essential medical testing solutions across the market.
Average Trading Volume: 785,265
Technical Sentiment Signal: Buy
Current Market Cap: A$537.3M
See more data about ACL stock on TipRanks’ Stock Analysis page.